Please monitor funder sites for all requirements, eligibility, deadlines, and events as they are subject to change.
FUNDING OPPORTUNITIES - NEW
FUNDING OPPORTUNITIES - ONGOING
AWARDS and HONOURS
FUNDING OPPORTUNITIES – NEW
Alex's Lemonade Stand Foundation (ALSF) – Reach Grant
Internal Deadline : April 7, 2026
External Deadline: April 14, 2026, 8:00p.m. (ET)
The goal of this award is to support translational studies that will result in a phase I and/or II clinical trial, two to three years from the project end date. Examples of appropriate research projects include but aren’t limited to, completing IND-enabling studies, providing requisite pre-clinical data for clinical trial development, or validating biomarkers that will enable patient selection for new clinical trials.
More Information
American Association for Cancer Research
Internal Deadline : April 1, 2026
External Deadline: April 9, 2026 1:00 PM (EST)
Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship
The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship is a joint effort to support and encourage innovative research projects with direct applicability and relevance to ILC and to help establish a successful career path in the field.
This fellowship provides a two-year grant of $130,000 to support the salary and benefits of postdoctoral or clinical research fellows working on mentored ILC research projects. If eligibility is based on a future position, the position must be confirmed at the time of submission and CANNOT be contingent upon receiving this grant.
Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Innovation and Discovery
The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Innovation and Discovery Grants is a joint effort to stimulate and develop creative, paradigm-shifting ideas in ILC research to ultimately contribute to development of new treatment options that may not be funded through conventional channels.
Each grant provides $50,000 over one year for expenses related to the research project Up to 5% of grant funds may be used on indirect costs.
More Information
American Association for Cancer Research -EMD Serono “I’M IN” Oncodisparity Fellowship for Bladder Cancer
Internal Deadline : February 17, 2026
External Deadline: February 24, 20261:00 PM (EST)
The AACR-EMD Serono “I’M IN” Oncodisparity Fellowship for Bladder Cancer represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct cancer disparities research and establish a successful career path in this field. The proposed research should specifically address disparities in oncology care in the area of bladder cancer and address barriers leading to inequality of cancer care that exist in institutions and within society at large.
The fellowship provides a one-year grant of $65,000
More Information
American Association for Cancer Research - Cancer Disparities Research Fellowship
Internal Deadline : March 5, 2026
External Deadline: March 12, 20261:00 PM (EST)
The AACR Cancer Disparities Research Fellowship represents an effort to encourage and support postdoctoral or clinical research fellows to conduct cancer disparities research and to establish a successful career path in this field. The proposed research may be in basic, translational, clinical, or population sciences research and must have direct applicability and relevance to cancer disparities.
The fellowship provides a two-year grant of $130,000
More Information
American Association for Cancer Research - KidneyCAN Kidney Cancer Innovation and Discovery Grants
Internal Deadline : March 5, 2026
External Deadline: March 12, 20261:00 PM (EST)
The 2026 AACR-KidneyCAN Kidney Cancer Innovation and Discovery Grants seek to stimulate creative approaches to translate basic research into new treatment options for kidney cancer.
These grants provide $50,000 over one year. Indirect costs are not allowable expenses.
More Information
Bladder Cancer Advocacy Network – 2026 Young Investigator Award
Internal Deadline : February 13, 2026
External Deadline: February 23, 2026 5:00 PM (EST)
This Award is intended to support the development of outstanding research scientists and
clinical cancer research investigators who have demonstrated a commitment to improving
the understanding, treatment, and/or experience of bladder cancer and/or upper tract
urothelial cancer. Investigators may be working in basic, translational, clinical, epidemiologic,
bioengineering or any other field, but they must be working in a research environment capable
of supporting transformational bladder cancer research. Additionally, investigators may be
working in a research environment capable of supporting transformational patient-oriented
clinical bladder cancer research (e.g. studies of shared decision making, access to care,
quality of care, quality of life, health disparities, comparative effectiveness research, patient-centered outcomes research, and survivorship).
More Information
CIHR - REDI Early Career Transition Award 2025 202606ECN
Internal Deadline : June 9, 2026
External Deadline: June 16, 2026
The CIHR Research Excellence, Diversity and Independence (REDI) Early Career Transition Award Program is intended to advance scientific excellence and foster diversity in Canada’s research ecosystem. It supports the professional development and career progression of trainees to establish and sustain strong, independent research programs in academia.
The REDI Award is designed to support trainees who are aiming to launch an independent research career in Canada, and would benefit from 1-3 years of structured, mentored development to support that transition.
The REDI Award has two phases across a maximum of 6 years:
Phase 1 (mentored): includes a research allowance, stipend, mentorship, and career development.
Applicants will propose a Research Plan for Phase 1 and 2 that demonstrates their long-term vision for their independent research program and how their Phase 1 project will build the foundation for their research independence in Phase 2. Applicants must work with their Primary Mentor (see eligibility for definition) to develop Mentorship and Career Development Plans and identify how they will distinguish their proposed research from their Primary Mentor’s (see FAQ for more details).
Awardees will begin seeking an independent research faculty position during Phase 1 and are expected to transition to this position – marking the start of Phase 2 – within 3 years of the funding start date.
Phase 2 (independent): includes a research allowance, salary support, faculty mentorship, and 1:1 matching of funds from the host institution.
The maximum amount per award is $660,000 for up to 6 years, funded through two specific phases.
More Information
CFI JELF – UBC Information for June 2026 Submission
See attached email.
Lung Cancer Research Foundation
2026 LCRF Prevention and Early Detection Research Grant Program
2026 LCRF Research Grant on Overcoming Resistance in Lung Cancer
2026 LCRF Leading Edge Research Grant
Internal Deadline CLOI: March 3, 226
External Deadline CLOI: March 10, 2026
Internal deadline (Invited): May 26, 2026
External deadline (Invited): June 2, 2026
2026 LCRF Prevention and Early Detection Research Grant Program
This funding mechanism is focused on identifying, characterizing, and developing approaches and
techniques that will allow early detection and/or prevention of lung cancer and gaining insight into preneoplastic processes in the lungs. The ultimate goal is to detect lung cancer at the earliest stages and
subsequently increase survival and survivorship.
The maximum award amount is $150,000 for a period of two years (disbursed at $75,000 per year).
Applicants may only apply for one LCRF grant per grant cycle.
2026 LCRF Research Grant on Overcoming Resistance in Lung Cancer
This grant mechanism will focus on furthering the understanding of the development, prevention, and therapy of resistance by supporting projects that seek to identify, characterize, treat or prevent resistance to lung cancer therapies. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship.
2026 LCRF Leading Edge Research Grant
The 2026 LCRF Leading-Edge Research Grant Program supportds innovative projects with novel methodologies across the full spectrum of basic, translational, clinical, epidemiological, health services, disparities, and social determinants of health research. 2026 LCRF Leading-Edge Research Grant Program will provide $150,000 over a period of two years (75,000 / year).
Go to https://proposalcentral.com/ and login under the “Application Login” section.
More Information
MOHCCN Health Informatics & Data Science Award
CLOI Internal deadline: Past
CLOI External deadline: Past
Internal Deadline : April 2, 2026
External Deadline : April 9, 2026
The MOHCCN Health Informatics & Data Science Award will provide outstanding early-career researchers with funding to support high-quality research in precision oncology. The award supports graduate (Master’s or PhD) and postdoctoral researchers in health informatics, data science, or related fields who are using MOHCCN data to advance innovative approaches to cancer prevention, diagnosis, and/or treatment.
Support under this RFA is targeted at high-quality, clinically relevant research using MOHCCN data, providing information that may form the basis of innovative cancer prevention, diagnosis and/or treatment advances. The total value of the awards is $100,000 ($50k from the Network, to be matched by the applicant's host institution).
More Information
OUCH-Int’l and LCRF Research Grant Program on the Effects of Air Pollution and Climate Change on Carcinogenesis and Lung Cancer Prevalence
Internal Deadline: May 26, 2026
External Deadline: June 2, 2026
This award’s objective is to fund innovative projects to support research that examines the impact of climate change and environmental pollution on lung cancer risk, diagnosis, treatment, and outcomes and identifies strategies to mitigate these effects.
The maximum award amount is $200,000 for a period of two years (disbursed at $100,000 per year). Up to 10% of the funding from this award may be used to support institutional indirect /facilities and administrative costs.
Go to https://proposalcentral.com/ and login under the “Application Login” section.
More Information
Pfizer - Independent Research Grants
Internal Deadline: April 17, 2026; September 1, 2026
External Deadline: April 22, 2026 ; September 9, 2026
Pfizer supports Investigator Sponsored Research (ISR) projects that advance medical and scientific knowledge about their therapies.
An ISR is a type of grant that supports an independent research study where the investigator or organization is the sponsor of the study and where Pfizer provides financial and/or non-financial support for the development or refinement of specific and defined medical knowledge relating to a Pfizer asset. This global program is open to all researchers who are interested in conducting their own research. This grant type is used as support for pre-clinical and clinical studies (including interventional and non-interventional), that involve a Pfizer asset (e.g., commercial drug, investigational drug, pure compound*).
Qualified researchers are invited to submit investigator-sponsored research (ISR) and General Research proposals, according to the guidance and instructions found on the Pfizer ISR portal at www.Pfizer.com/ISR.
More Information
The Stephenson Global Pancreatic Research Institute - Scholar Grant
CLOI Internal deadline Round 1: February 18, 2026
CLOI External deadline Round 1: February 25, 2026 at 5:00 p.m. Eastern Time
Internal deadline (Invited) Round 2: To be announced
External deadline (Invited) Round 2: To be announced
The Stephenson Global Scholar Grant is open to investigators worldwide whose research may help advance the field of pancreatic cancer through prevention, early detection, treatment, and/or other areas.
Projects should embody groundbreaking approaches and creative solutions to address key challenges in pancreatic cancer. Funding amounts will be determined based on the scale and potential impact of the proposed project. Indirect costs are capped at 10% of the total award amount.
More Information
Team Jack Foundation - Pediatric Brain Cancer Research Grant
CLOI Internal Deadline : April 7, 2026
CLOI External Deadline: April 30, 2026, 8:00p.m. (ET)
Internal deadline (Invited) :To be announced
External deadline (Invited) : To be announced
The number one priority of the Team Jack Foundation is to award research grants for the most promising programs and studies which will lead to a better understanding of the causes and treatment of pediatric brain cancer, well as the discovery of more effective treatments and a cure for children’s brain tumors.
Proposals related to basic and translational* projects that can advance understanding of underlying biology of the development and treatment of child brain tumors will be considered.
Award funding based on size, impact and complexity of project. Funding can be awarded over one, two or three year period,
More Information
FUNDING OPPORTUNITIES - ONGOING
AACR - Anna D. Barker Basic Cancer Research Fellowship 2026
CLOI Internal deadline: Past
CLOI External deadline: Past
Internal deadline (Invited): Past
External deadline (Invited): March 3, 2026 1:00pm ET
The AACR Anna D. Barker Basic Cancer Research Fellowship encourages and supports postdoctoral and
clinical research fellows to establish a successful career path in cancer research. The proposed project
may be in any area of basic cancer research. This fellowship provides a two-year grant of $110,000
Competitive Letter of Intent and Invited Full Application submitted on ProposalCentral.
More Information
BC Cancer - 2026 Summer Research Studentship Competition
Deadline: February 27, 2026 at 5:00 pm Pacific
Summer research studentships, sponsored by the BC Cancer Foundation, will be available to support senior undergraduate university students and/or junior medical or dental students seeking hands-on training in cancer research in BC during the period of May 1 – August 31, 2026.
3rd to 5th year (at time of application) undergraduate university students and 1st and 2nd year (at time of application) medical or dental students, who have not previously received a BC Cancer Summer Research Studentship, are eligible.
Summer research studentships may address any discipline of cancer research including: clinical, translational, basic, behavioral and population.
These awards may be held at any BC Cancer site of operation in the province, but are restricted to applicants planning to work on a research project that is funded and supervised by a senior health professional that has a full Research or Faculty appointment with BC Cancer.
The guidelines and application form are attached. Late applications will not be accepted.
Email any Queries to: studentship@bccrc.ca
Canada Foundation for Innovation – Innovation Fund 2027 at UBC
BC Cancer SigPkg Deadline – Competitive Letter of Intent: April 27, 2026
UBC Deadline – Competitive Letter of Intent: May 4, 2026
Internal Deadline – Application by Invitation: October 26, 2026, 10:00 am PT
External Deadline – Application by Invitation: November 2, 2026
In preparation for the anticipated Innovation Fund 2027 competition please see below, UBC’s internal timeline for the 2027 Innovation Fund competition ahead of the CFI call for proposals
*Please note, dates are subject to change as new information is released from the CFI (tentative CFI deadlines highlighted in blue, tentative Provincial deadline highlighted in grey).
The IPO will communicate CFI deadlines and confirm the UBC internal processes and timeline once we hear from the CFI.
| 2025 |
| UBC Internal Expression of Interest (EOI) | December 10, 2025 |
| 2026 |
| CFI launches draft call for proposals | Spring 2026 |
| CFI launches call for proposals | Spring 2026 (1 month following draft call) |
| UBC Internal deadline: Full internal proposal, including budget, CVs; UBC CFI envelope request for non-UBC lead projects. | May 04, 2026 |
| Internal review panel | June 22, 2026 |
| UBC internal decision – Applicants notified | July 06, 2026 |
| CFI NOI – UBC internal deadline | 3 days prior to CFI NOI deadline |
| CFI deadline to submit notice of intent (NOI) | October 2026 |
| UBC Internal Deadline: full proposal submission to IPO for formative review | November 02, 2026 |
| Formative review | November 03 – December 07, 2026 |
| Draft BCKDF Step 1 deadline | December 07, 2026 |
| Finance review and finalization | November 2026 to Feb 2027 |
| 2027 |
| UBC Internal Deadline for final proposal | Late January 2027 |
| CFI Deadline to submit proposals (expected) | February 2027 |
| UBC Internal Deadline for final BCKDF Step 1 | March 2027 (1-2 weeks after CFI submission) |
| BCKDF Deadline to submit Step 1 application | March 2027 (1 month after CFI submission) |
| CFI review process | March 2027 – November 2027 |
| CFI board of directors announce decision | November 2027 |
Pre-Competition Support
UBC CFI advisor, J9 Austin and the IPO team continue to be available to provide early-stage constructive feedback to allow potential applicants to develop the strongest proposal possible. Participation in test-your-concept (TYC) sessions at the early stages of proposal development is strongly encouraged as it will help applicants structure a timeline for planning and due diligence that will create a strong competitive advantage.
In particular, projects that may have significant construction or renovations in the budget will be required to participate in this process. Projects identifying major (Tier 4, Tier 5) construction/renovation costs at a later date (early 2026) are unlikely to be able to proceed since there will be insufficient time to go through the required institutional due diligence, and to fulfil CFI requirements. To determine your renovations or construction needs, please consult the Renovation and Infrastructure Cost Estimates (RICE) page
Please request a consult or Test Your Concept session here.
Canada Foundation for Innovation – John Evans Leadership Fund
Full information about UBC IPO processes and timelines for JELF proposals are available here.
Cancer Research Institute – Clinic and Laboratory Integration Program
CLOI Internal deadline: Past
CLOI External deadline: Past
Internal deadline (Invited): February 23, 2026
External deadline (Invited): March 2, 2026
This program is designed to support translational cancer immunology research — projects that bridge laboratory discovery and clinical application. Focus areas include: using basic immunology to solve clinical problems, translating preclinical findings into therapies, biomarker discovery, resistance mechanisms, and building models to improve immunotherapy.
Funding amount is $300,00 USD over two years, CRI also provides up to 10% indirect costs.
There is a possibility of a second phase extension: an additional US$ 300,000 over 2 more years, awarded during year 2 if the project has made “exceptional progress.”
More Information
Cancer Research Institute – Clinical Innovator Grant
Protocol Concept Internal deadline: Past
Protocol Concept (initial) deadline: Past
Internal deadline (Invited): March 27 2026
External deadline (Invited): April 4, 2026
The CRI Clinical Innovator supports pioneering immunotherapy clinical trials designed and led by academic researchers. These investigator-initiated studies are vital to improving patient outcomes, addressing areas of high unmet need, and generating critical mechanistic insights that can guide the future of cancer treatment.
The CRI Clinical Innovator funds innovative phase I/II or phase II clinical studies with a strong emphasis on:
Novel immunotherapy approaches
Mechanistic investigations into clinical response
The discovery and/or validation of predictive biomarkers
This award will support up to $1M per trial with up to 10% of the total award as indirect costs.
More Information
Canadian Cancer Society – Glioblastoma (GBM) Research Award Pre-Announcement
Registration Deadline: To be confirmed
Internal Deadline: A minimum of five (5) business days in advance of external deadline
External Deadline: February 2026
CCS and the Lundin Cancer Fund are excited to announce a new funding opportunity designed to catalyze innovative, high-impact research in glioblastoma (GBM) by supporting focused projects that rapidly assess proof-of-concept ideas. Emerging from the Lundin-CCS GBM Discovery Summit held in June 2025, these projects will employ an iterative co-development process to optimize innovation.
The program will officially CCS Opportunities begin accepting applications in February 2026, with more information to follow. Visit the CCS Funding Opportunities page regularly for the latest updates
CIHR - Beyond Treatment - Advancing Cancer Survivorship Team Grants
Anticipated Launch: Fall 2025
Registration: Winter 2026
Internal deadline: To be determined
External deadline: Summer 2026
The Canadian Institutes of Health Research (CIHR) is pleased to announce the upcoming launch of the Beyond Treatment: Advancing Cancer Survivorship Team Grants.
The Beyond Treatment: Advancing Cancer Survivorship Team Grants aims to unite interdisciplinary research teams to advance the biological understanding of the risks and development of late and long-term toxicities associated with cancer treatments, as well as strategies to improve survivorship care post-treatment, in relation to host, lifestyle, environmental, social, and other intersectional factors. Collaborations between existing cancer survivorship researchers (e.g., population and public health researchers, epidemiologists, psychosocial researchers) and experts from other disciplines new to the field (e.g., cardiology, endocrinology, musculoskeletal, neuroscience, reproductive and sexual health) are strongly encouraged. Collectively, these research teams will develop and disseminate evidence-based insights and solutions to enable improvements in cancer survivorship at the individual and/or population level.
CIHR will be hosting webinar(s) to inform participants about the requirements of this funding opportunity and to answer questions. To find out more information and to register, visit the Webinars page.
The maximum amount per grant is anticipated to be $400,000 per year for up to five (5) years, for a total of $2,000,000 per grant.
More Information
CIHR – Project Grant 2026 202603-PJT
Registration deadline: Past
Internal deadline: February 18, 2026 - with private sector partner (UBC)
Internal deadline: February 24, 2026 - without private sector partner
ResearchNet deadline: February 24, 2026 - with private sector partner (UBC)
ResearchNet deadline: March 3, 2026 without private sector partner (UBC)
External deadline: March 4, 2026
The Project Grant program is designed to capture ideas with the greatest potential for important advances in fundamental or applied health-related knowledge, health care, health systems, and/or health outcomes by supporting projects of research proposed and conducted by individual researchers or groups of researchers in all areas of health. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches.
Allow for extra processing time and review by for applications that include private sector partners.
Please note that starting May 1, 2024, new federal research security requirements apply to applications for research funding from the Tri-Agencies and Canada Foundation for Innovation when the project aims to advance certain sensitive technology research areas. The CIHR Project Grant program is affected by these changes. Please review the policies and whether they are applicable to your application via UBC Research Security website and by completing the Federal research security funding policy self-check.
More Information
The Colorectal Cancer Alliance - Project Cure CRC
Letter of Intent Deadline: Rolling deadline
Internal Deadline: minimum of five (5) business days in advance of application submission
External Deadline – by Invitation: Rolling deadline
The Colorectal Cancer Alliance (the Alliance) is pleased to announce a Request for Proposals (RFP) for preclinical, translational and clinical research with the potential for high impact on treatment and survivorship of colorectal cancer. Project Cure CRC will prioritize proposals that embrace moving colorectal cancer research to a curative science ASAP.
All Letters of Intent must be submitted to ProposalCENTRAL. Upon submission, proposals will be reviewed to determine if the proposal has adhered to Project Cure CRC RFP instructions
Young Investigator Accelerator Awards aim to attract early career faculty with original ideas into
the field of colorectal cancer research, thereby recruiting and supporting the next generation of CRC research
leaders. Awardees will be provided funding to accomplish innovative and original, preclinical, translational,
and/or early clinical research projects.
Amount: Up to $100,000 per year for two years (up to $200,000 total)
Senior Investigator Accelerator Awards will fund potentially transformative ideas that will
accelerate the translation of new therapies and technologies to the bedside by the end of the proposed
research. Collaborations are highly encouraged.
Amount: Up to $250,000 per year for two years (up to $500,000 total)
Pilot Accelerator Awards support investigators who propose potentially transformative ideas
without extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for
such "high-risk, high-reward" projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues.
Amount: Up to $100,000 per year for two years (up to $200,000 total)
The Team Science Accelerator Award will support team science, including public-private
partnerships, that will accelerate CRC research to curative science. Research proposals will be considered
that accelerate new therapeutic and technology innovations from bench to bedside and address unmet
clinical needs.
Amount: Up to $250,000 per year for two years (up to $500,000 total)
For applications that include private partnerships, consult the Technology Development Office before starting your application. tdoadmin@phsa.ca
More Information
International Waldenstrom Macroglobulinemia Foundation (IWMF) – Research Grants 2026
LOI Deadline: Past
Internal Deadline: February 20, 2026
External Deadline: February 27, 2026
For 2026, IWMF is seeking proposals for research and clinical studies that will deliver therapeutic benefits for WM patients within the next 3–5 years. Grant amounts range from $250K–$1M over 2–4 years, with a
separate award to support young investigators.
Pilot Clinical Trial Grants
WMF seeks to support independent investigators affiliated with academic institutions using investigator-initiated trials (IITs) to undertake clinical studies of novel agents, novel combinations, or new immunotherapies with potential for clinical breakthroughs in Waldenstrom macroglobulinemia (WM) patients. These clinical studies are designed to demonstrate proof-of-concept and produce compelling results in a limited number of patients. Successful study results will provide validation to initiate larger clinical studies to achieve new therapy inclusion in NCCN Guidelines, FDA approval, or other comparable regulatory approvals in the future. Amount: Up to $1M USD Duration: Over 2 - 4 years. Indirect costs are included in the total Grant Award and are limited to 20% of the total grant award value.
Translational Research Grants
IWMF seeks to support translational research studies with a focus on 1) uncovering new features of Waldenstrom macroglobulinemia (WM) biology and cellular vulnerabilities; 2) investigating mechanisms of WM relapse and therapy resistance; and 3) identifying and advancing research on therapeutically novel, therapeutically exploitable targets that represent under-explored opportunities. Amount: $500,000 - $750,000 USD Duration: Over 3-4 years. Indirect costs are included in the total Grant Award and are limited to 20% of the total grant award value.
Correlative Companion Research Grants
IWMF seeks to support correlative companion research studies within pharmaceutical and biotechnology company-sponsored trials for Waldenstrom macroglobulinemia (WM) patients that will be instrumental in determining the optimal use of new therapeutics under study. These projects leverage biological samples collected during trials to explore and validate biomarkers, mechanisms of response or resistance, or disease biology response to therapeutic intervention that will inform future clinical studies.
Amount: Up to $250,000 USD Duration: over 2 years. Indirect costs are included in the total Grant Award and are limited to 20% of the total grant award value.
Acceleration and Expansion Research Grants
IWMF seeks to support research studies to: 1) accelerate existing and additional IWMF Grants requiring further funding based on a novel, testable hypothesis that drives the additional funded research work toward translational and clinical applications (an Acceleration Grant); or 2) expand funding support for novel, translational mechanisms or targets, based on previous proof-of-concept work that may or may not have previous evidence of activity in B-cell malignancies (an Expansion Grant). Indirect costs are included in the total Grant Award and are limited to 20% of the total grant award value.
More Information
Leukemia & Lymphoma Society of Canada – Blood Cancer Research Grants 2026
Physician Scientist Fellow Award
LOI External deadline: Past
Internal deadline (Invited): Past
External deadline (Invited): February 18 4:00pm ET
This Fellow Award is specifically targeted at MDs near, or recently at, the completion of specialty training in hematology, oncology, hematopathology, pathology, or other related disciplines and who have initiated or have immediate plans to begin supervised research training directed at blood cancers. This opportunity is designed to foster, through provision of a contribution to their salary, the acquisition of skills and independence to conduct research in blood cancers at the laboratory, clinical or combined levels.
This is a two-year grant designed to provide funding to early-stage specialist clinicians. This award will provide funding for salary only for up to $85,000 per year for two years.
More Information
Lung Cancer Canada - 2026 Lung Ambition Awards
Internal deadline: Past
External deadline: February 20, 2026
The program is a partnership between Lung Cancer Canada, The Lung Ambition Alliance, and AstraZeneca Canada. For 2026, a total of $100,000 CAD will be awarded, split into two grants of up to $50,000
each to support Canadian research projects aimed at improving lung cancer care, including early detection, timeliness, and equity.
Questions? Contact Winky Yau at winky@lungcancercanada.ca
More Information
New Frontiers Research Fund – Transformation Award
NOI deadline: Past
CLOI Internal deadline: Past
CLOI UBC deadline: Past
Internal deadline: February 24, 2026
External deadline: March 3, 2026
The NFRF Transformation stream is designed to support large-scale, Canadian-led interdisciplinary research that address fundamental challenges, leading to a scientific breakthrough, or applied challenges, with a social, economic, environmental, or health impact.
Note new research security requirements relating to the Policy on Sensitive Technology Research and Affiliations of Concern.
There is a three-stage application process: Mandatory Notice of Intent (NOI), Mandatory Letter of Intent (LOI), and Full Application.
Minimum $2,000,000 per year (including indirect costs) over six years
Maximum $4,000,000 per year (including indirect costs) over six years
All applications to the 2026 New Frontiers in Research Fund - Transformation competition must be electronically submitted via the Convergence Portal.
For UBC applicants: Please submit the eligibility form to ors@ors.ubc.ca by: Letter of Intent Stage: June 11, 2025.
More Information - UBC
Pfizer Inc. - Oncology-Lung cancer: advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)
Internal Deadline: Past
External Deadline: February 18, 2026 (11:59 pm ET)
:Projects that will be considered for this RFP will focus on enhancing the knowledge of patients and care partners in the following areas:
• Preparation of patients and care partners for ALK inhibitor therapy, side-effect management, including what to expect during treatment and how to engage with their healthcare team.
• Development of material pertaining to prompt side-effect (adverse events) recognition, including lifestyle recommendations, to preserve / support quality of life.
• Development of tools that emphasize patient preferences, facilitate preference-informed decision-making, and ensure inclusivity and accessibility for example: providing multilingual resources.
Individual projects requesting up to $100,000 USD will be considered. Maximum project length is 18 months.
More Information
Terry Fox Research Institute - 2026 MOHCCN Clinician Scientist Awards
Internal Deadline: Past
External Deadline: February 17, 2026 (3:59 pm PT)
The MOHCCN Clinician Scientist Awards will provide outstanding young clinician investigators with funding to support high-quality research in precision oncology. Valued at $525,000 and tenable for three years, the award aims to support young investigators as they develop their careers as independent clinician-scientists in close collaboration and mentorship with established MOHCCN-funded teams.
BC Cancer applicants contact Jessica Nelson jnelson@bcgsc.ca or Alexander Cheong acheong@bcgsc.ca
More Information
The V Foundation – Pediatric Cancer Research Grant
Competition Launch: Past
BC Cancer Internal deadline: February 20, 2026
CLOI UBC deadline: February 27, 2026
Internal (Invited) deadline: March 13, 2026* estimated
External (Invited) deadline: March 23, 2026
UBC will be nominating two individuals to apply for the Pediatric Cancer Research Grants: one Translational or V Scholar nominee plus one All-Star nominee, if eligible.
The Pediatric Cancer Research Award is a special V Foundation grant designed to specifically support pediatric cancer research. Research areas not included in this scope for any grant type are epidemiology, behavioral science, and health services research. A biostatistical or bioinformatics plan is required for all proposals. Proposals without this element will not be considered for funding.
There will be up to two candidates selected for full application. There are three possible grant mechanisms.
- V Scholar - $600,000 over three years. No indirect costs allowed.
- Translational- $800,000 including indirect costs over four years
- AllStar- $1,000,000 including indirect costs over five years. Limited to one application
More Information
AWARDS AND HONOURS
Canadian Academy of Health Sciences Fellowship
External Deadline: March 11, 2026
The Canadian Academy of Health Sciences recognizes individuals of great accomplishment and achievement in the academic health sciences in Canada. Election to fellowship in the Academy is considered one of the highest honours for individuals in the Canadian health sciences community and carries with it a covenant to serve the Academy and the future well-being of the health sciences.
More Information
Dr. Chew Wei Memorial Prize in Cancer Research
External Deadline: February 27, 2026
The Dr. Chew Wei MBBS [HK] FRCOG [ENG] Memorial Prize in Cancer Research will be awarded annually to a Canadian physician or scientist who makes outstanding contributions to the treatment, amelioration, or development of therapies for cancer. One prize of $50,000.00 CAD will be awarded annually to a Canadian physician or scientist.
More Information
Institute for Health Metrics and Evaluation (IHME) - Roux Prize
External Deadline: March 3, 2026
The Roux Prize honours individuals or groups from around the world who have used health evidence in bold, innovative and impactful ways. IHME encourage the submission of competitive nominations of members of groups typically underrepresented in scientific awards and within the population health community at large. One prize of $100,000.00.
UBC Information
More Information
Order of British Columbia
External Deadline: April 7, 2026
Any British Columbian (or former long-term resident) who has demonstrated outstanding achievement, excellence or distinction in any field.
More Information
Ovarian Cancer Canada - The Anita Unruh Prize 2026
External Deadline: February 27, 2026
The Prize rewards excellence in trainee research on ovarian cancer and encourages trainees to establish careers in research related to this disease. Offered biannually, this is a peer-reviewed prize for a published paper that both focuses on ovarian cancer and has a trainee as first author. This competition is open to all trainees doing research on ovarian cancer.
$5,000 + registration and travel for the Canadian Conference on Ovarian Cancer Research, taking place from May 29-June 1, 2026 in Vancouver.
More Information
Stephenson Global Pancreatic Cancer Research Institute - Stephenson Global Prize
External Deadline: May 1, 2026 11:59:00 PM ET
The Stephenson Global Prize is a $1 million annual award established by the Stephenson Global Pancreatic Cancer Research Institute to recognize and honor individuals or teams whose scientific contributions have significantly advanced pancreatic cancer research. It highlights impactful achievements in areas such as early detection, prevention, treatment, and scientific discovery, celebrating work that has transformed understanding or treatment of the disease.
The global prize recognizes past achievements, and laureates may use the $1 million award to support their ongoing professional work.
More Information
EVENTS and ANNOUNCEMENTS
IOP Research Day
Registration Deadline: Monday, February 23th, 2026
The IOP Caucus is pleased to announce that registration and abstract submissionfor IOP Research Day are now open.
In lieu of BIGResearch Day, the IOP Caucus is organizing a series of themed research days to promote student engagement and to bring in new and exciting speakers. For this IOP Research Day, our theme is Drug Development & Therapeutic Resistance.
IOP Research Day: Drug Development & Therapeutic Resistance will take place in person on March 13th, 2026, at the BC Cancer Research Institute. This event provides an opportunity for graduate students to present their research, engage with peers, and attend seminars delivered by invited academic speakers. Coffee and lunch will be provided throughout the day.
- Students whose research aligns with this theme are encouraged to register and submit an abstract to be considered for a short oral presentation.
- Students whose research does not fall within this theme should register only.
- Undergraduate students and trainees from other programs with an interest in this topic are also welcome to attend.
Key dates:
- Abstract submission deadline: Monday, February 16th, 2026
- Registration deadline: Monday, February 23th, 2026
Important links:
Registration & abstract submission (https://forms.gle/qoXtUS2wqUHb5UMx5)
If you have any questions, please don’t hesitate to contact the IOP Caucus at iopcaucus@gmail.com.
This email lists some of the most commonly accessed funding mechanisms at BC Cancer and their associated deadlines. The listing is maintained by the Office of Research Administration. If you can not find information on a particular Funding Announcement, please contact a Grants Officer at ORA. While ORA has made every attempt to ensure that the information contained in this listing has been obtained from reliable sources, the Office of Research Administration is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in this email is provided "as is", with no guarantee of completeness, accuracy, timeliness. Sponsor requirements and deadlines are subject to change. It is the applicant's responsibility to stay current with any changes in the funding opportunity requirements. The information contained in this email is intended solely to provide general guidance on BC Cancer internal deadlines & Sponsor external deadlines.
Please note that all applications/co-applications/proposals/competitive letters of intent are to be approved by The Office of Research Administration (ORA) using a BC Cancer Research Coversheet and accompany a copy of the application signature package for ORA records. Applicants are advised to allow a minimum of five (5) for processing. NOTE: The ORA signature package is required prior to e-Submission or paper submission of the application by the applicant to the funding agency regardless of whether or not an institutional signature is required by the Sponsor/Funder.
Contact the OFFICE OF RESEARCH ADMINISTRATION:
BC Cancer
Office of Research Administration
675 West 10th Avenue, Vancouver, BC
604-675-8251
khagan@bccancer.bc.ca